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G
astric cancer is the
second most impor-
tant cancer worldwi-
de. It has a long pre-
cancerous latent period during
which it can be identified. The patho-
logical process has been carefully
established by which H. pylori cau-
ses either duodenal ulcers and a re-
duced risk of gastric cancer or a pre-
cancerous cascade ending in atro-
phic gastritis then gastric cancer.
Once the patient has been host to H.
pylori for three or four decades se-
vere gastric atrophy occurs and is
difficult to reverse.
Whether a screening programme
for Helicobacter pylori will be both
successful and cost-effective de-
pends on several factors: the percep-
tions of patients and physicians of
the importance of the condition; the
pre-test probability of infection; the
perceived reduction in the risk of
gastric carcinoma by identification
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Introduction: The aim of this review is to assess whether a screening programme for Helicobacter pylori will be both successful and cost-
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Database of Abstracts of Reviews of Effectiveness; MEDLINE; EMBASE; SilverPlatter, Biological Abstracts and Science Citation Index-
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Evaluation of the Level of Evidence: We used the rating system of the American Family Physician journal: Level A (randomized controlled
trial/meta-analysis); Level B (other evidence); and C (consensus/expert opinion).
Results: Serological tests: Antibody levels persist in serum for many years and do not permit us to distinguish between past and present
infection or to identify treatment failures.
Saliva and urine tests: A saliva test had sensitivity of 81% and specificity of 73%. A urine test had sensitivity of 86-89% and speci-
ficity of 69-91%.
Breath urea tests: The tests have a high sensitivity and specificity but require expensive equipment.
Stool tests: showed a high sensitivity and specificity. The European Helicobacter study group recommends either the breath urea or stool
antibody tests in the initial diagnosis of H. pylori.
Tests for specific gene sequences showed a high sensitivity and specificity.
Endoscopy: is invasive, uncomfortable for patients, and expensive.
The cost-effectiveness of tests for H. pylori: The better accuracy of the stool and breath tests, despite their greater cost, make them
more cost-effective than the serology or near-patient tests.
Conclusions: Tests with good sensitivity and specificity are available. The costs of non-invasive diagnostic tests acceptable to patients
have been worked out, and the cost-effective dominance of stool and particularly urea breath tests over serological tests has been deter-
mined in a systematic review. What remains is to implement and test further the cost-effectiveness of national testing strategies.
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and treatment of H. pylori and pre-
cancerous conditions; the ease and
comfort of the diagnostic tests; the
sensitivity and specificity of the tests;
the costs of diagnosis and treatment;
the effectiveness of treatment; the
relief from associated symptoms of
dyspepsia; and the overall cost-effec-
tiveness of treatment from the
viewpoint of society.
The aim of this review is to assess
whether a screening programme for
Helicobacter pylori will be both suc-
cessful and cost-effective.
Method
Searches: We searched the Cochra-
ne Central Register of Controlled 
Trials (CENTRAL), the Cochrane Da-
tabase of Systematic Reviews and
the NHS Database of Abstracts of
Reviews of Effectiveness (DARE) (all
to Cochrane Library Issue 1, 2006);
MEDLINE (OVID, January 1966 to
April 2006 week 1); EMBASE (Dia-
log 1974 to 1979; SilverPlatter 1980
to April 2006 week 1), Biological Abs-
tracts (SilverPlatter 1969 to April
2006) and Science Citation Index-
-Expanded (Web of Science 1974 to
April 2006). We used the search
terms Helicobacter pylori and (diag-
nos$ or identif$ or find$) and (syste-
matic review$ or meta-anal$), and
searched for articles in all languages
and limited the search to humans.
The Science Citation Index-Expan-
ded was used to identify articles that
cite the relevant studies. The rele-
vant studies were also keyed into
PubMed and the Related Articles fe-
ature used. We selected for review all
those articles which, from their abs-
tract or title, appeared to be rele-
vant, and obtained full-text versions
of the abstract or title to assess them
fully. We then reviewed all the rele-
vant articles in full text.
Evaluation of the Level of Evi-
dence: We used the rating system of
the American Family Physician: Le-
vel A (randomized controlled trial/
/meta-analysis); Level B (other evi-
dence); and C (consensus/expert
opinion).1
The operational qualities of tests
for H. pylori
Non-invasive tests are either direct
(bacterial antigens in stool) or indi-
rect (labelled CO
2 
in breath; IgG an-
tibodies to H. pylori in serum)2 [Evi-
dence Level B, non-quantitative re-
view]
Serological tests:Antibody levels
persist in serum for many years and
do not permit us to distinguish
between past and present infection
or to identify treatment failures.
However, if the patient has never re-
ceived any antibiotic therapy the
presence of antibodies likely indica-
tes persistent infection. A meta-ana-
lysis of 21 studies of ELISA serology
found an average sensitivity of 85%
and specificity of 79%.3 [Evidence
Level A, meta-analysis]. The UK De-
partment of Health evaluated sixte-
en ELISA kits and found an avera-
ge 78% accuracy (range 68-82%).4
[Evidence Level A, meta-analysis].
Near-patient ELISA tests in an
analysis in 1999-2000 had an ave-
rage sensitivity of 71% and specifi-
city of 88%.5 [Evidence Level A, meta-
-analysis].
Saliva and urine tests: A saliva
test had sensitivity of 81% and spe-
cificity of 73%.6 [Evidence Level B,
clinical cohort study]. A urine test in
an initial trial with 132 patients had
sensitivity of 86% and specificity of
91%; and in a large multicentre 
trial the sensitivity was 89% and the
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specificity 69%.7 [Evidence Level B,
clinical cohort study].
Breath urea tests: H. pylori pro-
duces urease which splits urea into
ammonia and CO2. The urea breath
tests measure the CO2 produced by
H. pylori. The test which uses 14C
has a sensitivity of 97% and a spe-
cificity of 95%5 [Evidence Level A,
meta-analysis], requires a scintilla-
tion counter and has many disad-
vantages compared to the 13C non-
radioactive test. The 13C test requi-
res an initial expense of buying a
mass spectrophotometer but, be-
cause it is not radioactive, has the
additional advantage that it can be
used with children and pregnant fe-
males. It has a sensitivity of 95%
and specificity of 96%.5 [Evidence Le-
vel A, meta-analysis]. The 13C test
which uses urea in a tablet form per-
mits sampling ten minutes after in-
gestion with the same accuracy as
after 30 minutes.8, 9 [Evidence Level
B, clinical cohort studies]. The excel-
lent review by Gisbert and Pajares10
discusses the factors that affect the
accuracy of the test and notes that
the original cut-off point of 5% for a
positive test needs to be modified for
the dose of urea used and whether
the test is the screening or post-tre-
atment test. Sensitivity and specifi-
city were 100% for a urea dose of
125mg and a cut-off point as low as
2.4% but the best sensitivity and
specificity for a dose of urea of 250
mg was at a cut-off point of 4.4%.
For the screening test the sensitivity
of 97.5% and specificity of 96.7%
were achieved with a cut-off point of
4.0% but for the follow-up test after
treatment the sensitivity and speci-
ficity were only 80% and 97.6% with
the same cut-off of 4.0%, while sen-
sitivity improved to 82.8% at a cut-
off of 3.5%, 88.6% at 3.0%, and
94.3% at 2.5% whilst specificity re-
mained at 95.2% for each of these
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cut-off points. [Evidence Level A,
meta-analysis].
Stool tests: Polyclonal antibody
tests used on stool specimens
showed a sensitivity of 93% and spe-
cificity of 93%.5 [Evidence Level A,
meta-analysis]. A systematic review
of 89 studies with 10,858 patients
found that the stool test, compared
to two other tests or the urea breath
test, had a sensitivity of 91%, a spe-
cificity of 93%, a positive predictive
value of 92%, and a negative predic-
tive value of 87%. For 39 studies
with 3,147 patients in whom eradi-
cation was tested four or more weeks
after completion of therapy, the sen-
sitivity was 96%, the specificity 97%,
the positive predictive value 96%
and the negative predictive value
97%. The monoclonal is more accu-
rate than the polyclonal test in both
the pre- and post-treatment set-
ting.11 [Evidence Level A, meta-ana-
lysis]. Yee assessed the accuracy for
187 patients of stool tests on sam-
ples frozen at –70 ºC for an average
of 120 days and found that sensiti-
vity was 84%, specificity 98%, the
positive predictive value 97% and
the negative predictive value 89%.12
[Evidence Level B, clinical cohort
study]. The European Helicobacter
study group recommends either the
breath urea or stool antibody tests
in the initial diagnosis of H. pylori.13
[Evidence Level A, Consensus con-
ference based on meta-analyses].
Tests for specific gene sequen-
ces: The HeloriCTX anti-Cag ELISA
test showed a sensitivity of 100%
and specificity of 75% and the Eu-
rospital It test showed 90% and 94%
for the cag gene sequence which
makes the H. pylori strains which
possess it more likely to be associa-
ted with severe atrophic gastritis and
gastric cancer.14
[Evidence Level B, clinical cohort
study]
Endoscopy: Endoscopy is invasi-
ve, uncomfortable for patients, and
expensive. For 708 dyspeptic pa-
tients, McColl found that, for those
under 55 years with uncomplicated
dyspepsia, the “test and treat” stra-
tegy was as safe and as effective as
endoscopy.15 [Evidence Level A,
RCT]. Arents found that the “test
and treat” strategy and prompt en-
doscopy had similar outcomes for
dyspeptic symptoms, quality of life
and satisfaction and that the “test
and treat” strategy resulted in 62%
fewer endoscopies.16 [Evidence Level
A, RCT]. The “test and treat” strategy
in a UK study had an average 
cost of £205.67 (approximately
302,46 €)* and endoscopy was
£404.31 (594,57 €).17 [Evidence Le-
vel A, RCT].
The American Gastroenterologi-
cal Association (1998), The Maas-
tricht 2 Consensus Report and the
European Society for Primary care
Gastroenterology 18, 19 have all recom-
mended a test and treat strategy wi-
thout endoscopy for those under 45
or 55 and with no alarm symptoms
(weight loss, anemia, dysphagia, pal-
pable mass, or malabsorption). [Evi-
dence Level C, consensus conferen-
ce].
The cost-effectiveness of tests
for H. pylori
The better accuracy of the stool and
breath tests, despite their greater
cost, make them more cost-effective
than the serology or near-patient
tests.20 [Evidence Level A, decision
analysis].
The sensitivity and specificity of a
test do not change with the preva-
lence of H. pylori, but the predictive
probability changes with the pre-test
probability for groups of individuals
(e.g those with a duodenal ulcer are
more likely to have H. pylori) or po-
pulations with higher prevalences. A
decision analysis was undertaken
using US Medicare fees for 2000 and
estimates of test performance from
studies of the highest methodologi-
cal quality. It identified 15 testing
strategies as dominant on grounds
of both cost and effectiveness. The
averaged costs used for ELISA tests
were US$76 (approximately 42 €)†,
for stool tests $118 (65.56 €), and
for breath tests $176 (97.78 €).20
[Evidence Level A, decision analy-
sis].
• At low H. pylori prevalence (30%)
the preferred test was the stool
test with 93% accuracy and cost
per correct diagnosis of $95
(52.78 €). The ELISA serological
test was 80% accurate and the
cost per correct diagnosis was
$95 (52.78 €).
• At intermediate prevalence (60%)
the preferred test was again the
stool test with 93% accuracy and
cost per correct diagnosis of $126
(70 €). The ELISA test was 82%
accurate and the cost per correct
diagnosis was $92 (51.1 €).
• At high prevalence (90%) the pre-
ferred test was the ELISA followed
by a urea breath test for the ne-
gatives, which provided 96% ac-
curacy and the cost per correct di-
agnosis was $117 (65 €).
• At low and intermediate prevalen-
ce, if the cost of the urea breath
test could be lowered below $50
(36.1€), it became preferable to
the stool test; and if the stool test
cost more than $82 (45.56 €),
then the stool test became prefe-
rable.
• Fingerstick whole blood tests are
not cost-effective because of their
low sensitivity and specificity.
Watabe followed 6,983 of the
*The average exchange rate in the 1st trimester
of 2006 of £0.68 for 1€ has been used.
†The average exchange rate in the 1st trimester
of 2006 of US$1,8 for 1€ has been used.
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hort study].
Hiyama studied sixty patients
with H. pylori in Hiroshima in 2000,
and using gene analysis, found re-
sistance to clarithromycin in 20%, to
metronidazole in 15% and to both in
8%.24 [Evidence Level B, clinical co-
hort study].
For preventing recurrence of duo-
denal ulcers, a systematic review
found that H. pylori eradication the-
rapy was not statistically superior
to maintenance therapy with ulcer
healing medications (RR ulcer recur-
ring = 0.73; 95% CI = 0.42 to 1.25)
but was superior to no treatment
(RR 0.19; 95% CI = 0.15 to 0.26). For
preventing gastric ulcer recurrence,
H. pylori eradication therapy was su-
perior to no treatment (RR= 0.31;
95%CI = 0.19 to 0.48).22 [Evidence
Level A, meta-analysis].
Tests with good sensitivity and spe-
cificity are available. The costs 
of non-invasive diagnostic tests
acceptable to patients have been
worked out and the cost-effective do-
minance of stool and, particularly,
urea breath tests over serological
tests has been determined in a
systematic review. Post-treatment
serological tests may remain positi-
ve for months whereas urea and
stool tests will be promptly negative
if eradication therapy was suc-
cessful. What remains is to imple-
ment and test further the cost effec-
tiveness of national testing strate-
gies. These need to begin with local
pilot schemes in specific areas to test
the willingness of health personnel
to undertake regular and complete
screening of the identified target po-
pulation and to measure the costs
of each link of the testing strategy in
specific countries.
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9,293 participants in a health-scre-
ening programme in Tokyo.21 The
ELISA test in this Japanese popula-
tion had a sensitivity of 95% and
specificity of 83%, while the pepsi-
nogen test had 70% sensitivity and
97% specificity for atrophic gastritis
compared to histology. They were
able to identify groups at high risk
of gastric cancer: those who had
“atrophic” levels of pepsinogen I and
were H. pylori negative (in severe
atrophic gastritis H. pylori tends to
disappear) had an annual risk of
gastric cancer of 0.6%; those with
“atrophic” pepsinogen levels and H
pylori positive 0.35%; and those with
normal pepsinogen levels had rates
of 0.04-0.06%. [Evidence Level B,
clinical cohort study].
A systematic review concluded
that for healing duodenal ulcers H.
pylori eradication therapy was supe-
rior to medications for healing ulcers
(RR [relative risk] of ulcer persisting
= 0.66; 95% CI = 0.58 to 0.76) and
superior to no treatment (RR = 0.37;
95% CI = 0.26 to 0.53). For healing
gastric ulcers H. pylori eradication
therapy was not statistically superior
to medications for healing ulcers (RR
= 1.32; 95% CI = 0.92 to 1.90). The
Markov model suggested that H.
pylori eradication is cost-effective for
duodenal ulcers at one year and for
gastric ulcers at two years with more
than 95% confidence.22 [Evidence Le-
vel A, meta-analysis].
In a study of 4,930 patients with pe-
ptic ulcer the total recurrence rate
after treatment was 3%, with 2.3%
of gastric, 1.6% of gastroduodenal
and 1.6% of duodenal ulcers recur-
ring.23 [Evidence Level B, clinical co-
RECURRENCE OF ULCERS AFTER
TREATMENT, AND RESISTANCE
TO ANTIBIOTICS
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RESUMO
Introdução: O objectivo desta revisão é avaliar a segurança e custo-efectividade de um programa de ras-
treio de Helicobacter pylori.
Metodologia: Pesquisámos o Cochrane Central Register of Controlled Trials, o Cochrane Database of
Systematic Reviews e o NHS Database of Abstracts of Reviews of Effectiveness; MEDLINE; EMBASE;
SilverPlatter, Biological Abstracts and Science Citation Index-Expanded. Usámos os termos de pesquisa
Helicobacter pylori e (diagnos$ or identif$ or find$) e (systematic review$ or meta-anal$), e pesquisámos
artigos de todas as línguas limitando a pesquisa a humanos.
Avaliação do Nível de Evidência: usámos o sistema de classificação da revista American Family Physician:
Nível A (ensaios clínicos aleatorizados/meta-análises). Nível B (outras fontes de evidência). Nível C (con-
sensos/opinião de peritos).
Resultados: Testes serológicos: os níveis de anticorpos persistem no soro durante vários anos e não nos
permitem distinguir entre infecção presente e passada ou identificar o insucesso do tratamento.
Testes de saliva e urina: um teste de saliva tinha sensibilidade de 81% e especificidade de 73%; um teste
de urina tinha sensibilidade de 86-89% e especificidade de 69-91%.
Testes respiratórios com ureia: os testes têm uma sensibilidade e especificidade altas mas requerem equipa-
mento caro.
Teste fecal: demonstrou uma alta sensibilidade e especificidade. O European Helicobacter study group
recomenda a utilização do teste respiratório com ureia ou o teste fecal no diagnóstico inicial de H. Pylori.
Os testes de sequenciação genética demonstraram elevada sensibilidade e especificidade.
Endoscopia: é invasiva, desconfortável e cara.
O custo-efectividade dos testes para o H. Pylori: a maior precisão dos testes fecal e respiratório, apesar do
seu custo, fazem com que sejam mais custo-efectivos do que a serologia ou outros testes.
Conclusões: Existem testes com boa sensibilidade e especificidade. Foram examinados os custos dos testes
não-invasivos aceitáveis para os pacientes: um maior custo-efectividade do teste fecal e, particularmente,
do teste respiratório da ureia em relação aos testes serológicos foi determinado numa revisão sistemáti-
ca. Seria necessário implementar e testar o custo-efectividade de estratégias nacionais de rastreio.
Palavras-chave: Helicobacter Pylori; Diagnóstico; Rastreio Populacional; Análise de Custo-benefício; Meta-análise; Revisão
Sistemática.
